

Pembrolizumab as a first line therapy in a patient with extensive Mucoepidermoid salivary gland carcinoma. A complete clinical, radiological and pathological response. A very specific case

Raed Farhat (✉ raed.frhat88@gmail.com)

Ziv Medical Center

Noam Asna

Ziv Medical Center

Yaniv Avraham

Ziv Medical Center

Ashraf Khater

Ziv Medical Center

Majd Asakla

Ziv Medical Center

Alaa Safia

Ziv Medical Center

Nidal Elkhatib

Ziv Medical Center

Shlomo Merchavy

Ziv Medical Center

Case Report

Keywords: Pembrolizumab, salivary gland cancers (SGCs): immunotherapy, complete response (CR)

Posted Date: March 11th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1433947/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: The treatment options for patients with advanced salivary gland cancers (SGCs) are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) scoring in SGCs. The benefit of chemotherapies was reported to be minimal with a prognosis that remains poor in unresectable and high grade SGC.

Immunotherapies have shown remarkable success in various entities not limited to non-small cell lung cancer and malignant melanoma. Pembrolizumab, an anti-PD-1 antibody, has been proven to have strong anti-tumor activity in a variety of clinical studies.

Case presentation: We report a unique case of advanced high grade mucoepidermoid carcinoma of the parotid salivary gland after Pembrolizumab treatment as a first line therapy.

Pembrolizumab treatment resulted in downstaging of the tumor which lead to its successful surgical resection with no facial nerve sacrifice and no serious side effects of the neoadjuvant treatment, and the final specimen pathology was free of tumor. A similar strategy that resulted in complete response (CR) radiologically and pathologically has never been mentioned before in these kind of tumors.

Conclusions: Pembrolizumab has demonstrated a promising antitumor activity in pretreated patients with high grade salivary gland mucoepidermoid carcinoma, and offered a clinically, radiological and pathological response with a meaningful therapeutic option. Further studies that move the treatment of Pembrolizumab to front-line are necessary. These studies should include the time and duration of the pharmacotherapy in relation to the needed time of surgery.

Introduction

Salivary gland carcinoma (SGC) is a rare tumor and represents ~6% of head and neck cancers¹. Regardless of its histological subtype, curative treatment consists of a surgical resection with or without postoperative adjuvant radiation therapy^{2,3,4}.

Mucoepidermoid carcinoma (MEC) is a malignant tumor predominantly arising from the salivary glands; the minor glands preferentially give rise to MEC^{5,6}. MEC is the most frequent malignant salivary gland tumor in children and adults⁶.

Although adjuvant treatment options like chemotherapy or radiation do not have a detectable impact on survival in highly aggressive subtypes like salivary duct carcinomas⁷. There is also no standard treatment or proven efficacy for patients with unresectable primaries/recurrences or patients with distant metastasis². The benefit of chemotherapies like combinations of cisplatin, doxorubicin and cyclophosphamide was reported to be minimal with a prognosis that remains poor^{2,9,10}.

Immunotherapies have shown remarkable success in various entities not limited to non-small cell lung cancer and malignant melanoma. All these therapies share a similar mode of action directing the body's own immune system to dispose of tumor cells^{11,12}.

Pembrolizumab is a fully humanized immunoglobulin G4/ κ anti-PD-1 monoclonal antibody. Pembrolizumab has demonstrated robust antitumor activity and a favorable safety profile in multiple tumor types and is currently approved in over 60 countries for 1 or more advanced malignancies, including in the United States for recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum containing chemotherapy.^{13,14,15}

The recently published KEYNOTE-048 trial established a new standard in this setting with the introduction of immunotherapy, either alone or in combination with chemotherapy¹⁶.

This article reports a unique case of unresectable advanced high grade mucoepidermoid carcinoma of the salivary gland with complete response after Pembrolizumab treatment as a first line therapy. A similar strategy has never been tried in high grade salivary gland tumors, and complete radiological and pathological responses have never been reported before in this kind of tumors.

This treatment resulted in downstaging of the tumor and led to its successful surgical resection.

Case Presentation

A 68-year-old male, diabetic with a forty pack-year smoking history presented with an enlarging left, slightly tender, rapidly progressive swelling of the left parotid gland during the previous 6 months before our first examination. The patient was referred to head and neck clinic, Department of Otolaryngology Head and Neck Surgery, Ziv Medical Center in Safed, in the north of Israel.

Physical examination showed a firm, immobile, slightly tender, 3 × 3 cm left parotid mass with overlying skin change (**Fig. 1**), with multiple hard, immobile lymph nodes, 3 * 2 cm, at level II,III,V of the left neck, the remainder of the head and neck examination was unremarkable. Flexible nasendoscopy findings of the nasopharynx, oropharynx, and larynx were unremarkable.

Fine needle aspiration (FNA) of the left parotid mass was consistent with positive malignant cells for high grade mucoepidermoid carcinoma with mitosis.

Contrast-enhanced magnetic resonance imaging (MRI) revealed a lobulated, irregular mass, 37*39*47 mm located in the posteroinferior segment of the superficial and deep lobe in the left parotid gland, with areas of extensive central necrosis, septation, and peripheral wall enhancement contiguous with the anterior portion of external auditory canal and SCM muscle with subcutaneous tissue and skin involvement, several nodules in the left infraparotid area and level II were calcified (**Fig. 2**).

The 18F-FDG PET/CT revealed hypermetabolic activity within the mass in the left parotid gland with involvement of the skin, SCM muscle and several nodules in the left infraparotid area and level II,III in the

left neck (**Fig. 3**).

The final diagnosis was clinical stage IV (T4aN2bM0).

The patient was considered as high-grade MECs which progressed rapidly and caused pain, soft tissue invasion; these MECs are associated with poor overall survival, which approaches 40–50% at 5 years, and with an increased risk for locoregional and distant failures^{17,18,19}.

The recommended therapy for high-grade MECs includes surgical resection with selective neck dissection followed by adjuvant radiotherapy²⁰.

In our case, the high morbidity and mortality associated with the need of extensive surgical resection with free flap reconstruction and the massive loss of tissue with possible facial nerve sacrifice, in addition to increased risk for locoregional and distant failures led us to think about neoadjuvant treatment.

Pembrolizumab monotherapy was generally well tolerated in advanced Salivary Gland Carcinoma (SGC), with a safety profile that reflects previous experience of pembrolizumab in patients with advanced cancers²¹.

Treatment plan was made by a multidisciplinary team and after multiple discussions with the goal of maximizing survival with preservation of form and function.

Our patient received pembrolizumab intravenously at 200 mg every 2 weeks, with a good compliance.

From September 2021 to November 2021, he underwent 2 cycles of pembrolizumab with no side effects.

The MRI scan after 3 cycles revealed a significant decrease in the tumor or even its disappearance, and on examination WHEN? The patient had attained a complete remission in the clinic examination (**Fig. 4,5**).

Restaging with 18FDG PET-CT at 6 weeks after completion of immunologic treatment demonstrated a full resolution of the parotid gland metabolic activity. In the left neck, the nodal status had generally improved with no signs of hypermetabolic activity. High metabolic uptake was not seen elsewhere. (**Fig. 6**).

As a precaution, left parotidectomy and unilateral neck dissection levels I,II,III,IV were recommended for locoregional control and because of remaining morphological masses on ct. (**Fig. 7**).

All the 18FDG PET-CT scans performed are summarized in (Fig. 8).

Final pathological results showed no evidence of carcinoma neither in the parotid gland nor in the neck lymph nodes and had free margins.

The patient has continued to be supervised with CT scans and serum tumor marker measurements every 3 or 4 months and is still in complete remission at this time.

Discussion

This is the first report that describes complete resolution of high grade malignant salivary gland mucoepidermoid carcinoma with Pembrolizumab as a “first line” therapy treatment.

Cohen et al ²¹ reported the phase Ib KEYNOTE-28 experience using single-agent pembrolizumab 10 mg/kg once every 2 weeks in 38 PDL1 expressing recurrent-metastatic salivary gland carcinomas. This study did not report evidence of progression before participation, and the majority of enrolled participants had adenocarcinomas. Among 38 patients enrolled, three had a Partial Response (PR) with an overall response rate of 12% with a 3-month median duration of response. There were no complete remission responses.

There is no gold standard for management of advanced SGC, and existing therapies generally lack significant clinical benefit. Available data supporting use of traditional cytotoxic chemotherapy are based on small studies, many of which were conducted before contemporary analytical concepts (e.g, RECIST)²².

The prospective experience with the antiPD1 checkpoint inhibitors in salivary gland carcinomas consists of small phase I and II clinical trials, again with heterogenous histologies and variations in design and eligibility for such treatment.

Although pembrolizumab carries a primary site agnostic US Food and Drug Administration approval for mismatch repair–deficient tumors, it is important to note that this was based on a nine-patient cohort of non-colorectal cancer patients, none of whom had salivary gland malignancies^{23,24}.

The role of tumor mutation burden (TMB) is unclear in SGCs. The subgroup analysis by TMB from the KEYNOTE-158 trial led to the approval of pembrolizumab for patients with TMB > 10 mut/Mb as an agnostic treatment. There were three patients with salivary histology and high TMB, one of whom achieved partial response²³.

Although the current data from salivary gland malignancies trials are limited, our result in using Pembrolizumab as a first line agent in advanced high grade mucoepidermoid carcinoma suggests that this treatment remains a promising cancer therapy .

Further research studies which will evaluate the treatment of Pembrolizumab to front-line, maintenance settings, and trials of combinations with chemotherapy, radiotherapy or other immune checkpoints are very necessary.

Conclusion

In conclusion, Pembrolizumab has demonstrated a promising antitumor activity in pre-treated patients with high grade salivary gland mucoepidermoid carcinoma, and offered a clinically, radiological and

pathological response with a meaningful therapeutic option.

Further studies that move the treatment of Pembrolizumab to front-line, maintenance settings and combinations with other treatment methods are necessary. These studies should include the time and duration of the pharmacotherapy in relation to the needed time of surgery. Side effects of the drugs should also be followed as well as patient compliance.

References

1. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a sitespecific analysis of the SEER database. *Int J Cancer*. 2005;114:806–16. doi:10.1002/ijc.20740.
2. Mukaigawa T, et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. *J Surg Oncol*. 2016;114:36–43. <https://doi.org/10.1002/jso.24266>.
3. Garden AS, et al. Postoperative radiotherapy for malignant tumors of the parotid gland. *Int J Radiat Oncol Biol Phys*. 1997;37:79–85.
4. Terhaard CH, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. *Int J Radiat Oncol Biol Phys*. 2005;61:103–11. <https://doi.org/10.1016/j.ijrobp.2004.03.018>.
5. Strutz J, Mann WJ. *Praxis der HNO-Heilkunde*. Stuttgart: Thieme; 2009. p. 579.
6. Goode RK, El-Naggar AK. Mucoepidermoid carcinoma (Head and Neck). In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. *Pathology and genetics of Head and Neck Tumours*. Lyon: World Health Organization Classification of Tumours. IARC Press; 2005. pp. 219–22.
7. Osborn V, et al. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database. *Oral Oncol*. 2017;71:41–6. <https://doi.org/10.1016/j.oraloncology.2017.05.005>.
8. Sridharan V, et al. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. *Cancer Immunol Res*. 2016;4:679–87. <https://doi.org/10.1158/2326-6066.CIR-16-0031>.
9. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. *Lancet Oncol* 12, 815–24, [https://doi.org/10.1016/S1470-2045\(10\)70245-X](https://doi.org/10.1016/S1470-2045(10)70245-X) (2011).
10. Alberts DS, Manning MR, Coulthard SW, Koopmann CF, Herman TS. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. *Cancer*. 1981;47:645–8.
11. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat Rev Cancer*. 2016;16:275–87. <https://doi.org/10.1038/nrc.2016.36>.

12. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. *Cancer Control*. 2014;21:231–7.
13. Merck Sharp & Dohme Corp. Keytrudas (Pembrolizumab) injection, for Intravenous Use. Whitehouse Station: Merck Sharp & Dohme Corp; 2017.
14. Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. *J Clin Oncol*. 2016;34:3838–45.
15. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. *Lancet Oncol*. 2016;17:956–65.
16. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland A, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or meta-static squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. *Lancet*. 2019;394:1915–28. [CrossRef].
17. McHugh CH, Roberts DB, El-Naggar AK, et al. Prognostic factors in mucoepidermoid carcinoma of the salivary glands. *Cancer*. 2012;118:3928–36.
18. Chen AM, Lau VH, Farwell DG, et al. Mucoepidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: Clinicopathologic correlates of outcome. *Laryngoscope*. 2013;123:3049–55.
19. Brandwein MS, Ivanov K, Wallace DI, et al: Mucoepidermoid carcinoma: A clinicopathologic study of 80 patients with special reference to histological grading. *Am J Surg Pathol* 25:835–845, 2001
Crossref, Medline, Google Scholar.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Accessed on January 04, 2021).
21. Cohen R, Delord J, Doi T, Piha-Paul S, Liu S, Gilbert J, Algazi A, Damian S, Hong R, Le Tourneau C, Day D, Varga A, Elez E, Wallmark J, Saraf S, Thanigaimani P, Cheng J, Keam B. 2021. *Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma*.
22. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. *J Clin Oncol*. 2006;24:2673–8.
23. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol*. 2020;21:1353–65.

Declarations

This study was approved by the Helsinki Committee in Ziv Medical Institution.

Figures




Figure 1

Firm, immobile, slightly tender, 3*3 cm left parotid mass with overlying skin changes.

Figure 1

Legend not included with this version



A.MRI T1 lobulated, irregular mass, located in the posteroinferior segment of the superficial lobe in the left parotid gland, B.MRI T2 with areas of extensive central necrosis, septation C. several suspected lymph nodes in the left infraparotid area and level II and III D. peripheral wall enhancement

Figure 2

Legend not included with this version





Figure 3

The patient with metabolically active tumor prior to the initiation of immunotherapy with Pembrolizumab.

Figure 3

Legend not included with this version



MRI T1 and T2 - after 2 cycles of the neoadjuvant treatment shows significant decrease in the tumor or even its disappearance, attained a complete remission.

Figure 4

Legend not included with this version




Figure 5

The mass appearance after 2 cycles of neoadjuvant treatment.

Figure 5

Legend not included with this version



A complete metabolic response already 8 weeks after immunotherapy of Pembrolizumab initiation despite remaining morphological masses on CT.

Figure 6

Legend not included with this version




Figure 7

The patient underwent left parotidectomy with neck dissection and excision of the involved skin.

Figure 7


Legend not included with this version

Baseline prior to Pembrolizumab

Follow up 8 weeks after initiation

Baseline prior to Pembrolizumab

Follow up 8 weeks after initiation



Before

After

Before

After

Figure 8

Figure 8

Legend not included with this version